ML228

Research use only, not for human use.

ML228 (ML-228, CID-46742353) is an activator of the hypoxia inducible factor (HIF) pathway with EC50 of 1.4 uM in HIF-1α nuclear translocation assays.

ML228 (ML-228, CID-46742353) is an activator of the hypoxia inducible factor (HIF) pathway with EC50 of 1.4 uM in HIF-1α nuclear translocation assays; demonstrates to potently activate HIF in vitro as well as its downstream target VEGF (EC50=1.63 uM); significantly augmentes VEGFR-2, attenuates Caspase-3 and neuronal apoptosis, and improves neurological Severity Score and tissue edema in the hippocampus of rats, without affecting expression of NF-κB.

ML228 (CID-46742353) represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications.

ML228 (injection; 1 μg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function. Animal Model:SD rat Dosage:1 μg/kg Administration:injection; 7 days Result:Alleviated SCI of the central nervous system and relieve associated symptoms.

ML-228 | CID-46742353

Angiogenesis

HIF/HIF Prolyl-hydroxylase

HIF/HIF Prolyl-hydroxylase

Cancer

——

1357171-62-0

415.4891

C27H21N5

>98% (HPLC)

DMSO: ≥ 35 mg/mL

C1(C2=NC(NCC3=CC=C(C4=CC=CC=C4)C=C3)=C(C5=CC=CC=C5)N=N2)=NC=CC=C1

1,2,4-Triazin-5-amine, N-([1,1'-biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-

(-20℃)

With Ice Pack

≥ 2 years